Association of p53/ERβ expression and muscular invasion with the incidence of regional lymph node metastasis and/or postoperative recurrence in patients with endometrial endometrioid carcinoma.

<p>Association of p53/ERβ expression and muscular invasion with the incidence of regional lymph node metastasis and/or postoperative recurrence in patients with endometrial endometrioid carcinoma.</p

Disease-free survival curve of patients with p53-/ERβlow, p53+/ERβlow, p53-/ERβhigh, or p53+/ERβhigh in endometrial endometrioid carcinoma.

<p>Disease-free survival was significantly shorter in patients with p53-stained and high-ERβ (p53+/ERβhigh) than in other patients. Kaplan-Meier survival analysis showed that the disease-free survival of patients with p53-/ERβhigh was significantly shorter than that of patients with p53-/ERβlow and p53+/ERβlow. Patients with p53+/ERβhigh showed significantly shorter disease-free survival than those with p53-/ERβhigh (**: <i>p</i> < 0.01).</p

Clinicopathological data on 154 patients with endometrial endometrioid carcinoma.

<p>Clinicopathological data on 154 patients with endometrial endometrioid carcinoma.</p

DNA sequence analysis of the <i>TP53</i> gene in cases of endometrial endometrioid carcinoma.

<p>Representative results of sequencing of exon 8 in the <i>TP53</i> gene are shown. The upper panel shows a case of grade 3 endometrioid carcinoma with para-aortic lymph node metastasis and the wild-type sequence for reference (A). The lower panel shows a case of grade 2 endometrioid carcinoma without metastasis and a single nucleotide substitution, cytosine (C) to thymine (T), resulting in an arginine to cysteine substitution at codon 273 of the <i>TP53</i> gene (B).</p

Association of p53/ERβ expression and muscular invasion with the incidence of regional lymph node metastasis and/or postoperative recurrence in patients with endometrial endometrioid carcinoma.

<p>Association of p53/ERβ expression and muscular invasion with the incidence of regional lymph node metastasis and/or postoperative recurrence in patients with endometrial endometrioid carcinoma.</p

Association of positive ranges of p53 expression, <i>TP53</i> gene mutation, and the incidence of regional lymph node metastasis and/or postoperative recurrence in patients with endometrial endometrioid carcinoma.

<p>Association of positive ranges of p53 expression, <i>TP53</i> gene mutation, and the incidence of regional lymph node metastasis and/or postoperative recurrence in patients with endometrial endometrioid carcinoma.</p

Immunohistochemical localization of ERβ and p53 proteins in representative cases of endometrial endometrioid carcinoma.

<p>A and B, Grade 1 endometrial endometrioid carcinoma with low-ERβ (A) and non-stained-p53 (B). C and D, Grade 2 endometrial endometrioid carcinoma with low-ERβ and p53-stained (D). E and F, Grade 1 endometrial endometrioid carcinoma with high-ERβ (E) and non-stained-p53 (F). G and H, Grade 2 endometrial endometrioid carcinoma with high-ERβ (G) and p53-stained (H). Scale bars, 100 μm.</p

Univariate and multivariate analysis of factors affecting disease progression in 154 patients with endometrial endometrioid carcinoma.

<p>Univariate and multivariate analysis of factors affecting disease progression in 154 patients with endometrial endometrioid carcinoma.</p

Summary of the 29 cases with regional lymph node metastasis and/or postoperative recurrence of endometrial endometrioid carcinoma.

<p>Summary of the 29 cases with regional lymph node metastasis and/or postoperative recurrence of endometrial endometrioid carcinoma.</p